J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

Data Compilation
#PharmaFlow

Pipeline Prospector June 2025: Sanofi, AbbVie, Eli Lilly, BioNTech lead pharma M&A spree; BMS, Astra ink major collaborations

Stock Recap
#PipelineProspector

Valproic Acid

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

81 API Suppliers, 36 USDMF, 10 CEP/COS, 3 JDMF, 14 EU WC, 9 KDMF, 16 NDC API, 38 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

FINISHED DOSAGE FORMULATIONS

265 FDF Dossiers, 110 FDA Orange Book, 57 Europe, 17 Canada, 26 Australia, 17 South Africa, 38 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SYRUP;ORAL - 250MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 125MG VALPROIC ACID, TABLET, DELAYED RELEASE;ORAL - EQ 250MG VALPROIC ACID, TABLET, DELAYED RELEASE;ORAL - EQ 500MG VALPROIC ACID, CAPSULE, DELAYED REL PELLETS;ORAL - EQ 125MG VALPROIC ACID, TABLET, EXTENDED RELEASE;ORAL - EQ 250MG VALPROIC ACID, TABLET, EXTENDED RELEASE;ORAL - EQ 500MG VALPROIC ACID

RELATED EXCIPIENT COMPANIES

12 Evonik, 2 Rochem International Inc, 20 SPI Pharma, 17 DKSH, 1 Pharm-RX Chemical, 7 Faran Shimi Pharmaceutical, 11 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 9 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 8 Actylis, 1 Aeon Procare, 3 Alcedo Pharmachem, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 1 Avesta Pharma, 38 BASF, 2 Clariant, 18 Corel Pharma Chem, 6 DFE Pharma, 3 Doshion Polyscience, 1 Esteem Industries, 2 Finar, 13 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 14 Ideal Cures, 5 Ingredion Pharma Solutions, 34 Kerry, 3 Keval Exports, 4 Kima Chemical, 6 Lonza Capsugel, 18 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 5 Novo Excipients, 4 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 27 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 3 The Dow Chemical Company, 2 Ulanqab Kema New Material, 3 Valens Pharmachem, 4 Vasa Pharmachem, 2 Vertellus

EXCIPIENTS BY APPLICATIONS

103 Fillers, Diluents & Binders, 87 Coating Systems & Additives, 51 Controlled & Modified Release, 46 Disintegrants & Superdisintegrants, 43 Solubilizers, 42 Direct Compression, 42 Thickeners and Stabilizers, 37 Taste Masking, 35 Granulation, 30 Film Formers & Plasticizers, 27 Topical, 22 Lubricants & Glidants, 22 Co-Processed Excipients, 21 Parenteral, 18 Chewable & Orodispersible Aids, 13 Rheology Modifiers, 11 Emulsifying Agents, 9 API Stability Enhancers, 9 Empty Capsules, 6 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules

DIGITAL CONTENT

62 News #PharmaBuzz

62 News #PharmaBuzz

GLOBAL SALES INFORMATION

43 US Medicaid Prescriptions, 91 Regulatory FDF Prices, 5 Annual Reports

MARKET PLACE

27 APIs, 16 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM, 5 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
28/06/2025	EUROAPI	France	Sanofi-Aventis Korea Co., Ltd.	20210310-209-J-870	Valproic acid	2021-03-10	Sanofi Winthrop Industrie	France	Chem Pole 64, Avenue Du Lac, Mourenx, 64150, France
28/06/2025	SCI Pharmtech	Taiwan	Base Farm Co., Ltd.	20201125-209-J-769(2)	divalproex sodium	2022-05-17	SCI Pharmtech, Inc	Taiwan	No.61, Ln.309, Haihu N. Rd., Luzhu Dist. Taoyuan City 33856, Taiwan

Valproic Acid

Valproic Acid

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

81 API Suppliers

36 USDMF

10 CEP/COS

3 JDMF

14 EU WC

9 KDMF

16 NDC API

38 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

FINISHED DOSAGE FORMULATIONS

265 FDF Dossiers

110 FDA Orange Book

57 Europe

17 Canada

26 Australia

17 South Africa

38 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SYRUP;ORAL - 250MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 125MG VALPROIC ACID

TABLET, DELAYED RELEASE;ORAL - EQ 250MG VALPROIC ACID

TABLET, DELAYED RELEASE;ORAL - EQ 500MG VALPROIC ACID

CAPSULE, DELAYED REL PELLETS;ORAL - EQ 125MG VALPROIC ACID

TABLET, EXTENDED RELEASE;ORAL - EQ 250MG VALPROIC ACID

TABLET, EXTENDED RELEASE;ORAL - EQ 500MG VALPROIC ACID

RELATED EXCIPIENT COMPANIES

12 Evonik

2 Rochem International Inc

20 SPI Pharma

17 DKSH

1 Pharm-RX Chemical

7 Faran Shimi Pharmaceutical

11 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

9 Nanjing Well Pharmaceutical

2 Pfanstiehl

4 ACG Worldwide

8 Actylis

1 Aeon Procare

3 Alcedo Pharmachem

10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

1 Avesta Pharma

38 BASF

2 Clariant

18 Corel Pharma Chem

6 DFE Pharma

3 Doshion Polyscience

1 Esteem Industries

2 Finar

13 Gangwal Chemicals

1 Huzhou Sunflower Pharmaceutical

14 Ideal Cures

5 Ingredion Pharma Solutions

34 Kerry

3 Keval Exports

4 Kima Chemical

6 Lonza Capsugel

18 Microlex e.U

1 Nanjing Bold Chemical

2 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

5 Novo Excipients

4 Pharmatrans-Sanaq

7 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

27 Roquette

14 Seppic

CAPSULE;ORAL - 250MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SYRUP;ORAL - 250MG/5ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons